Debate

Low-dose stavudine trials: a public health priority for developing countries

W D Francois Venter, Steve Innes, Mark Cotton
Southern African Journal of HIV Medicine | Vol 13, No 1 | a154 | DOI: https://doi.org/10.4102/sajhivmed.v13i1.154 | © 2012 Copyright Status: Not provided. Contact Holding Institution to verify copyright status. Rights Holder: Southern African HIV Clinicians Society
Submitted: 15 December 2012 | Published: 13 March 2012

About the author(s)

W D Francois Venter, Wits Reproductive Health and HIV Institute (WRHI), Department of Medicine, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
Steve Innes, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa
Mark Cotton, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa

Abstract

The debate around relooking at stavudine dosing, both in terms of the adult low-dose stavudine study and more broadly, is welcome. The study being proposed to evaluate low-dose stavudine v. tenofovir is a fairly standard placebo-controlled non-inferiority study. The study design is not controversial; however, the choice of study drug has attracted critical attention.

Keywords

No related keywords in the metadata.

Metrics

Total abstract views: 4417
Total article views: 5410

 

Crossref Citations

1. Multistep Continuous Flow Synthesis of Stavudine
Cloudius R. Sagandira, Faith M. Akwi, Mellisa B. Sagandira, Paul Watts
The Journal of Organic Chemistry  vol: 86  issue: 20  first page: 13934  year: 2021  
doi: 10.1021/acs.joc.1c01013

2. Mass spectrometric investigations into the brain delivery of abacavir, stavudine and didanosine in a rodent model
Sipho Mdanda, Sphamandla Ntshangase, Sanil D. Singh, Tricia Naicker, Hendrik G. Kruger, Sooraj Baijnath, Thavendran Govender
Xenobiotica  vol: 50  issue: 5  first page: 570  year: 2020  
doi: 10.1080/00498254.2019.1655605

3. The ethics of expanding access to cheaper, less effective treatments
Govind C Persad, Ezekiel J Emanuel
The Lancet  vol: 388  issue: 10047  first page: 932  year: 2016  
doi: 10.1016/S0140-6736(15)01025-9

4. Antiretroviral dose reduction: good for patients and rollout
Jens D Lundgren, Andrew Phillips
The Lancet  vol: 383  issue: 9927  first page: 1442  year: 2014  
doi: 10.1016/S0140-6736(13)62556-8

5. Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing
Steve Innes, Louvina van der Laan, Peter L. Anderson, Mark Cotton, Paolo Denti
Antimicrobial Agents and Chemotherapy  vol: 62  issue: 11  year: 2018  
doi: 10.1128/AAC.00761-18

6. Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children
Julia Kenny, Victor Musiime, Ali Judd, Diana Gibb
Current Opinion in HIV and AIDS  vol: 7  issue: 4  first page: 305  year: 2012  
doi: 10.1097/COH.0b013e328354da1d